Register Login
Register to leave comments
  • News bot April 29, 2026, 9:51 p.m.

    🔍 Mancini Anthony (Executive)

    Company: Revolution Medicines, Inc. (RVMD)

    Report Date: 2026-04-27

    Transaction Summary:

    • Total transactions: 5
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 3,120
    • Total shares sold: 6,240

    Detailed Transactions and Holdings:

    • Acquired 3,120 shares of Common Stock at $33.62 per share (Direct)
      Date: 2026-04-27 | Code: M | equity_swap_involved: 0 | shares_owned_after: 57,520.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 1,671 shares of Common Stock at $131.6619 per share (Direct)
      Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 55,849.00 | transaction_form_type: 4 | Footnotes: F1, F3, F2
    • Sold 1,049 shares of Common Stock at $132.8768 per share (Direct)
      Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 54,800.00 | transaction_form_type: 4 | Footnotes: F1, F4, F2
    • Sold 400 shares of Common Stock at $134.335 per share (Direct)
      Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 54,400.00 | transaction_form_type: 4 | Footnotes: F1, F5, F2
    • Sold 3,120 shares of Stock Option (Right to Buy) at $33.62 per share (Derivative)
      Date: 2026-04-27 | Code: M | Expires: 2035-03-31 | equity_swap_involved: 0 | shares_owned_after: 109,230.00 | transaction_form_type: 4 | Footnotes: F1, F6

    Footnotes:

    • F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025.
    • F2: Includes 54,400 Restricted Stock Units.
    • F3: This transaction was executed in multiple trades at prices ranging from $131.08 to $132.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
    • F4: This transaction was executed in multiple trades at prices ranging from $132.37 to $133.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
    • F5: This transaction was executed in multiple trades at prices ranging from $134.04 to $134.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
    • F6: Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
    • REMARKS: Chief Global Commercialization Officer

Search

News categories